Anika Therapeutics, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Anika is a global joint preservation company focused on osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface joint solutions. The company’s portfolio combines hyaluronic-acid technology with products acquired through Parcus Medical and Arthrosurface. This unaudited Form 10-Q covers the three months ended March 31, 2023, with comparisons to the same period in 2022.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $37.9 million | $36.7 million | Up 3% |
| Gross profit | $22.8 million | $21.8 million | Up 5% |
| Gross margin | 60% | 59% | Up 1 percentage point |
| Research and development | $8.4 million | $6.2 million | Up 36% |
| SG&A | $27.0 million | $19.2 million | Up 41% |
| Loss from operations | $(12.6) million | $(3.6) million | Loss increased |
| Net loss | $(10.4) million | $(2.9) million | Loss increased $7.4 million |
| Diluted loss per share | $(0.71) | $(0.20) | Loss increased |
| Adjusted EBITDA | $(1.2) million | $2.6 million | Down $3.8 million |
| Cash used in operating activities | $(3.6) million | $(1.9) million | Use increased |
Revenue by product family was $22.6 million from OA Pain Management, $13.5 million from Joint Preservation and Restoration, and $1.8 million from Non-Orthopedic products. The company reported $79.7 million of cash and cash equivalents at March 31, 2023, compared with $86.3 million at December 31, 2022. Working capital was $131.6 million, compared with $141.6 million at year-end 2022.
Anika had no outstanding borrowings under its $75.0 million senior revolving credit facility and was in compliance with its terms. The facility may be expanded by up to an additional $75.0 million, subject to conditions. Lease liabilities totaled $28.3 million at March 31, 2023. Total assets were $339.1 million and stockholders’ equity was $277.6 million.
Material changes versus the prior comparable period
- Revenue increased 3%, led by 8% growth in OA Pain Management and 11% growth in Joint Preservation and Restoration.
- Non-Orthopedic revenue declined 49%, primarily because of distributor ordering timing and the end-of-life of certain legacy products.
- Gross margin improved to 60%, primarily due to improved production volumes.
- R&D increased by $2.2 million due to global regulatory compliance costs, new product development, and manufacturing scale-up activities.
- SG&A increased by $7.8 million. The increase included approximately $5.8 million of non-recurring costs related to the Parcus Medical arbitration settlement, shareholder activism, and other corporate costs, as well as higher commercial, marketing, and stock-based compensation expenses.
- The company recorded a $3.25 million liability for the Parcus Medical arbitration settlement at March 31, 2023. The settlement was entered into on April 20, 2023, and paid in April 2023.
- Cash declined by $6.6 million during the quarter, reflecting operating cash use, capital expenditures, and employee tax-withholding payments related to equity awards.
- The effective tax rate decreased to 13.9% from 20.9%, primarily because the company recorded a valuation allowance against U.S. deferred tax assets in light of expected 2023 operating losses.
- Management disclosed net losses for both periods. A discussion sentence in the filing referring to prior-year “net income” appears inconsistent with the consolidated financial statements, which report a Q1 2022 net loss of $2.9 million.
Guidance, outlook, commentary, risks, and unusual items
Management expects to continue investing substantially in research and development, commercial capabilities, and operational infrastructure. The filing states that the company expects to incur an operating loss for 2023 and that cash on hand, expected operating cash flows, and credit availability are expected to fund anticipated needs. No formal revenue or earnings guidance is provided.
Anika entered into a cooperation agreement with Caligan Partners on April 13, 2023. The agreement increased the board to eight directors and established a $20.0 million share repurchase program, including a $5.0 million accelerated share repurchase, a second $5.0 million open-market tranche, and a final $10.0 million tranche subject to positive cash flow. The prior $20.0 million open-market repurchase authorization was canceled.
- Key operating risks include regulatory approvals and compliance, product development and commercialization, competition, dependence on key personnel, protection of intellectual property, and supply-chain or staffing disruptions.
- The company remains exposed to COVID-19-related procedure delays, staffing shortages, supply-chain disruptions, and clinical-study delays, although the filing states the impact had been limited to those items to date.
- DePuy Synthes Mitek Sports Medicine represented 43% of Q1 2023 revenue, up from 39% in Q1 2022, indicating significant customer concentration.
- Inventory reserves increased to approximately $11.3 million from $9.9 million at December 31, 2022.
- Disclosure controls and procedures were not effective at March 31, 2023 because of material weaknesses in internal control over financial reporting previously disclosed in the 2022 Form 10-K. Remediation efforts are underway, but the weaknesses had not been remediated.
- The company may need additional financing if operating cash flows and existing resources become insufficient; the filing states that financing may not be available on acceptable terms.
Important facts for investors to verify
- Whether revenue growth in OA Pain Management and Joint Preservation and Restoration continues after distributor ordering variability.
- The magnitude and duration of elevated R&D and commercial infrastructure spending.
- The effect of the $20.0 million share repurchase program on cash balances and future liquidity.
- Progress and testing results related to remediation of the material weaknesses in internal controls.
- Customer concentration and any changes in the commercial relationship with DePuy Synthes Mitek Sports Medicine.
- Inventory levels, reserve adequacy, and potential additional product rationalization charges.
- Whether the company generates positive operating cash flow while pursuing its growth strategy and funding the repurchase program.